Surrozen Reports Q4 and Full Year 2025 Financial Results, Provides Business Update

Company expects to submit IND for SZN-8141 in second half of 2026, plans ARVO presentation on retinal vascular research

Mar. 24, 2026 at 6:19am

Got story updates? Submit your updates here. ›

Surrozen, a biotechnology company pioneering Wnt-based therapeutics for sight-threatening ophthalmic conditions, announced its financial results for Q4 and full year 2025 and provided a business update. Key highlights include plans to submit an Investigational New Drug (IND) application for lead candidate SZN-8141 in the second half of 2026, a $5 million milestone payment from partner Boehringer Ingelheim, and upcoming scientific presentations on the company's Wnt-based pipeline.

Why it matters

Surrozen's focus on developing novel Wnt-based therapies for retinal diseases like diabetic macular edema and wet age-related macular degeneration represents a promising approach to address significant unmet medical needs in ophthalmology. The company's pipeline and partnerships demonstrate its commitment to advancing this innovative science.

The details

In 2025, Surrozen continued to progress its lead candidates SZN-8141 and SZN-8143 for retinal diseases. The company expects to submit an IND application for SZN-8141 in the second half of 2026. Surrozen also received a $5 million milestone payment from partner Boehringer Ingelheim related to the IND-enabling studies for SZN-413. Additionally, the company strengthened its leadership team with key hires in clinical development and finance to support its long-term ophthalmology strategy.

  • Surrozen expects to submit an IND application for SZN-8141 in the second half of 2026.
  • In March 2026, Boehringer Ingelheim achieved a research milestone under the agreement for SZN-413, triggering a $5 million payment to Surrozen.
  • Surrozen plans to present retinal vascular research on SZN-8141 at the 2026 ARVO Annual Meeting on May 4, 2026.

The players

Surrozen, Inc.

A biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions.

Craig Parker

President and Chief Executive Officer of Surrozen.

Daniel Chao, M.D., Ph.D.

Vice President and Head of Clinical Development at Surrozen.

Andrew Maleki

Chief Financial Officer of Surrozen.

Boehringer Ingelheim International GmbH

A global pharmaceutical company that has a collaboration and license agreement with Surrozen for the development of SZN-413.

Got photos? Submit your photos here. ›

What they’re saying

“2025 was a year of significant momentum as we progressed two lead product candidates in retinal vascular disease, advanced our platform for developing multifunctional biologic candidates that selectively activate Wnt signaling in combination with other key disease pathways and further strengthened our management team to drive our long-term growth strategy.”

— Craig Parker, President and Chief Executive Officer of Surrozen

“2026 is an exciting year for us as we expect to submit an IND application for SZN-8141 in the second half of the year and continue our focus on developing therapeutics that address critical unmet needs in retinal diseases.”

— Craig Parker, President and Chief Executive Officer of Surrozen

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

Surrozen's progress in advancing its Wnt-based pipeline for retinal diseases, including plans to submit an IND for lead candidate SZN-8141, demonstrates the company's commitment to developing innovative therapies that could transform treatment for sight-threatening conditions like diabetic macular edema and wet age-related macular degeneration.